Authors: CooperDehoff Rhonda M Zhou Qian Pepine Carl J
Publish Date: 2005/05/01
Volume: 18, Issue: S4, Pages: 104A-104A
Abstract
Rhonda M CooperDehoff Qian Zhou Carl J Pepine P272 BP control and CV outcomes in hispanic and nonhispanic women with CAD and hypertension Findings from invest American Journal of Hypertension Volume 18 Issue S4 May 2005 Page 104A https//doiorg/101016/jamjhyper200503290An analysis of the 4909 Hispanic H women with CAD and HTN enrolled in the International Verapamil SR/Trandolapril Study INVEST was conducted and comparisons were made to the 6861 nonHispanic NH women with regard to baseline characteristics BP control and CV outcomes Patients were randomized to either a verapamil SR or an atenololbased antihypertensive strategy Dose titration and additional drugs trandolapril and/or HCTZ could be prescribed for BP control according to JNC VI goals The primary outcome PO was first occurrence of death nonfatal MI or nonfatal stroke There were no differences comparing the strategies with regard to CV outcomes in either H or NH womenAt 24 months BP control was achieved in 66 and 57 of H and NH women respectively p0001 and a majority of H and NH women were treated with /=2 strategy drugs 71 and 69 respectively 57 of H and 114 of NH women experienced the PO A stepwise model for time to PO adjusting for differences in baseline characteristics indicated a significant difference between H and NH women HR=087 95CI=078096 p=0008These data add significantly to what is known about hypertension and CAD in H and NH women BP can be significantly reduced with either a verapamil SR or atenolol strategy and requires treatment with more than one antihypertensive in most H women experienced significantly fewer adverse CV outcomes compared to NH women which is in part explained by significantly fewer baseline comorbidities
Keywords: